Eszter Lázár‐Molnár

2.9k total citations · 1 hit paper
40 papers, 2.2k citations indexed

About

Eszter Lázár‐Molnár is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Eszter Lázár‐Molnár has authored 40 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Immunology, 9 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Eszter Lázár‐Molnár's work include Immune Cell Function and Interaction (11 papers), Immunodeficiency and Autoimmune Disorders (8 papers) and Immunotherapy and Immune Responses (7 papers). Eszter Lázár‐Molnár is often cited by papers focused on Immune Cell Function and Interaction (11 papers), Immunodeficiency and Autoimmune Disorders (8 papers) and Immunotherapy and Immune Responses (7 papers). Eszter Lázár‐Molnár collaborates with scholars based in United States, Hungary and France. Eszter Lázár‐Molnár's co-authors include Xingxing Zang, Yu Yao, Amer Assal, Kim C. Ohaegbulam, Steven C. Almo, Stanley G. Nathenson, András Falus, Hargita Hegyesi, Sára Tóth and U.A. Ramagopal and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Immunology and FEBS Letters.

In The Last Decade

Eszter Lázár‐Molnár

39 papers receiving 2.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

2014 654 citations Kim C. Ohaegbulam, Amer Assal et al. Trends in Molecular Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eszter Lázár‐Molnár United States	19	1.1k	1.1k	608	269	240	40	2.2k
Annkristin Heine Germany	26	847 0.8×	662 0.6×	1.0k 1.7×	201 0.7×	208 0.9×	66	2.4k
Giuseppe Sconocchia Italy	32	1.2k 1.1×	1.1k 1.0×	698 1.1×	196 0.7×	94 0.4×	88	2.6k
Alfredo Perales‐Puchalt United States	26	1.4k 1.2×	1.1k 1.0×	999 1.6×	331 1.2×	90 0.4×	71	2.9k
Jonathan S. Maltzman United States	25	1.8k 1.6×	789 0.7×	765 1.3×	184 0.7×	115 0.5×	60	3.0k
Céline Bossard France	29	785 0.7×	888 0.8×	516 0.8×	229 0.9×	104 0.4×	97	2.2k
Fernando Aranda Spain	28	1.5k 1.3×	1.3k 1.3×	644 1.1×	156 0.6×	77 0.3×	76	2.5k
Frédéric Coutant France	17	1.3k 1.1×	665 0.6×	591 1.0×	429 1.6×	95 0.4×	29	2.2k
Michele Ardolino Canada	17	2.0k 1.8×	1.4k 1.3×	481 0.8×	159 0.6×	120 0.5×	31	2.7k
Sasikanth Manne United States	22	2.2k 1.9×	1.8k 1.7×	952 1.6×	215 0.8×	132 0.6×	32	3.4k
Elizabeth Richards United States	9	1.1k 1.0×	470 0.4×	331 0.5×	210 0.8×	110 0.5×	16	1.7k

Countries citing papers authored by Eszter Lázár‐Molnár

Since Specialization

Citations

This map shows the geographic impact of Eszter Lázár‐Molnár's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eszter Lázár‐Molnár with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eszter Lázár‐Molnár more than expected).

Fields of papers citing papers by Eszter Lázár‐Molnár

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eszter Lázár‐Molnár. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eszter Lázár‐Molnár. The network helps show where Eszter Lázár‐Molnár may publish in the future.

Co-authorship network of co-authors of Eszter Lázár‐Molnár

This figure shows the co-authorship network connecting the top 25 collaborators of Eszter Lázár‐Molnár. A scholar is included among the top collaborators of Eszter Lázár‐Molnár based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eszter Lázár‐Molnár. Eszter Lázár‐Molnár is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lázár‐Molnár, Eszter & Lisa K. Peterson. (2025). Clinical utility of the lymphocyte proliferation assay, an in vitro functional readout of the adaptive immune response. Journal of Immunological Methods. 537. 113819–113819. 1 indexed citations

Lázár‐Molnár, Eszter, et al.. (2024). Novel desensitization strategy in a highly sensitized heart/liver transplant candidate using imlifidase. Human Immunology. 85. 110893–110893.

Al‐Rabadi, Laith, Aaron J. Storey, Christopher P. Larsen, et al.. (2024). De novo Membranous Nephropathy in Renal Allografts is Associated With Protocadherin FAT1. Kidney International Reports. 10(1). 247–251. 3 indexed citations

Profaizer, Tracie, et al.. (2021). Comparison of Next-Generation Sequencing-Based Human Leukocyte Antigen Typing with Clinical Flow Cytometry and Allele-Specific PCR Melting Assays for HLA-B27 Genotyping. The Journal of Applied Laboratory Medicine. 6(5). 1221–1227. 4 indexed citations

Luo, Ruben Yiqi, Indrani Chakraborty, Eszter Lázár‐Molnár, Alan H.B. Wu, & Kara L. Lynch. (2020). Development of Label-Free Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and Antidrug Antibodies. Clinical Chemistry. 66(10). 1319–1328. 18 indexed citations

Lázár‐Molnár, Eszter, et al.. (2019). Inductively coupled plasma mass spectrometry assay for quantification of free infliximab in serum. Journal of Immunological Methods. 470. 33–39. 1 indexed citations

Yang, Yifei, et al.. (2018). Development and validation of a targeted affinity-enrichment and LC–MS/MS proteomics approach for the therapeutic monitoring of adalimumab. Clinica Chimica Acta. 483. 308–314. 9 indexed citations

Profaizer, Tracie, et al.. (2018). P082 HLA disease association testing by NGS: Is it superior to other methods?. Human Immunology. 79. 121–121. 1 indexed citations

Lázár‐Molnár, Eszter, et al.. (2015). Clinical laboratory application of a reporter-gene assay for measurement of functional activity and neutralizing antibody response to infliximab. Clinica Chimica Acta. 453. 147–153. 28 indexed citations

10.

Lázár‐Molnár, Eszter, et al.. (2015). The effect of pronase on lymphocyte surface markers and implications for flow cytometric crossmatch. Human Immunology. 76. 131–131. 2 indexed citations

11.

Ohaegbulam, Kim C., Amer Assal, Eszter Lázár‐Molnár, Yu Yao, & Xingxing Zang. (2014). Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine. 21(1). 24–33. 654 indexed citations breakdown →

12.

Scandiuzzi, Lisa, Kaya Ghosh, Kimberly A. Hofmeyer, et al.. (2014). Tissue-Expressed B7-H1 Critically Controls Intestinal Inflammation. Cell Reports. 6(4). 625–632. 54 indexed citations

13.

Lázár‐Molnár, Eszter & Anne E. Tebo. (2014). Autoimmune NMDA receptor encephalitis. Clinica Chimica Acta. 438. 90–97. 29 indexed citations

14.

Lázár‐Molnár, Eszter, Bing Chen, William R. Jacobs, & Stanley G. Nathenson. (2011). Inhibition through PD-1 is crucial for protection against M. tuberculosis infection (58.1). The Journal of Immunology. 186(1_Supplement). 58.1–58.1. 1 indexed citations

15.

Lázár‐Molnár, Eszter, Steven C. Almo, & Stanley G. Nathenson. (2006). The interchain disulfide linkage is not a prerequisite but enhances CD28 costimulatory function. Cellular Immunology. 244(2). 125–129. 20 indexed citations

16.

Lázár‐Molnár, Eszter, Hargita Hegyesi, Éva Pállinger, et al.. (2002). Inhibition of human primary melanoma cell proliferation by histamine is enhanced by interleukin‐6. European Journal of Clinical Investigation. 32(10). 743–749. 37 indexed citations

17.

Hegyesi, Hargita, J. Hunyadi, G. Martín, et al.. (2002). Cimetidine and a tamoxifen derivate reduce tumour formation in SCID mice xenotransplanted with a human melanoma cell line. Melanoma Research. 12(3). 231–240. 16 indexed citations

18.

Fitzsimons, Carlos P., et al.. (2001). Histamine deficiency induces tissue‐specific down‐regulation of histamine H2 receptor expression in histidine decarboxylase knockout mice. FEBS Letters. 508(2). 245–248. 27 indexed citations

19.

Kőhidai, László, Péter Kovács, Eszter Lázár‐Molnár, & G. Csaba. (2000). PRESENCE, UPTAKE AND LOCALIZATION OF AN IMMUNOREACTIVELY INTERLEUKIN 6 (IL‐6)‐LIKE MOLECULE IN TETRAHYMENA PYRIFORMIS. Cell Biology International. 24(10). 749–755. 9 indexed citations

20.

Lázár‐Molnár, Eszter, Hargita Hegyesi, Sára Tóth, & András Falus. (2000). AUTOCRINE AND PARACRINE REGULATION BY CYTOKINES AND GROWTH FACTORS IN MELANOMA. Cytokine. 12(6). 547–554. 341 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact